Help us make childhood cancer universally survivable.
By giving monthly, you directly support our continued research into discovering effective and less toxic treatments for childhood cancer.
Support Our Lab
Our team of scientists and engineers are on a mission...
We are a nonprofit biotech lab on a mission to make childhood cancer universally survivable. Every year, the FDA approves on average 12 drugs to treat adult cancer, but has only approved 6 drugs to treat childhood cancer since 1978. We believe it’s time to do better.
Let's do better for
#doingbettertogether
Latest News
Science Acceleration by Megan Cleary
Recently, I have been moving through the submission and peer review process for two manuscripts relating to side projects I have completed in the lab. The first manuscript investigates the combinatorial effect of the mek inhibitor trametinib with γ-secretase inhibitors on rhabdomyosarcoma cell viability. It was published in April on the pre-print server BioRxIV and can be found here: https://www.biorxiv.org/content/10.1101/622522v1. The second manuscript examines the efficacy of commercially available compounds which claim to inhibit the NF-κB pathway, then tests the most potent inhibitors on a patient derived cell culture of ependymoma. It was recently discovered
The “Early Days” of cc-TDI
Stella’s Grandmother Speaks
Science Notification: Project Haystack by Ken Crawford
In the Press
Current Research Projects
A dedicated research team
Our research team is exploring and testing state-of-the-art treatment options for the most urgent issues facing children with cancer.
Working in our own freestanding research institution allows us to act swiftly and nimbly to achieve results—bringing cost control, speed, purpose, and focus to translate effective treatments into the clinic. To get there, we perform basic science and translational research in our industrial modern lab site (a paint factory remodeled by Nike as an off-site creative space), adjacent to the Silicon Forest in Oregon.
